Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

877 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TPMT polymorphisms and minimal residual disease after 6-mercaptopurine post-remission consolidation therapy of childhood acute lymphoblastic leukaemia.
Dreisig K, Brünner ED, Marquart HV, Helt LR, Nersting J, Frandsen TL, Jonsson OG, Taskinen M, Vaitkeviciene G, Lund B, Abrahamsson J, Lepik K, Schmiegelow K. Dreisig K, et al. Among authors: lund b. Pediatr Hematol Oncol. 2021 Apr;38(3):227-238. doi: 10.1080/08880018.2020.1842570. Epub 2020 Nov 18. Pediatr Hematol Oncol. 2021. PMID: 33205673 Clinical Trial.
DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN, Grell K, Nersting J, Abrahamsson J, Lund B, Kanerva J, Jónsson ÓG, Vaitkeviciene G, Pruunsild K, Hjalgrim LL, Schmiegelow K. Nielsen SN, et al. Among authors: lund b. Lancet Oncol. 2017 Apr;18(4):515-524. doi: 10.1016/S1470-2045(17)30154-7. Epub 2017 Mar 1. Lancet Oncol. 2017. PMID: 28258828 Clinical Trial.
Minimal residual disease quantification by flow cytometry provides reliable risk stratification in T-cell acute lymphoblastic leukemia.
Modvig S, Madsen HO, Siitonen SM, Rosthøj S, Tierens A, Juvonen V, Osnes LTN, Vålerhaugen H, Hultdin M, Thörn I, Matuzeviciene R, Stoskus M, Marincevic M, Fogelstrand L, Lilleorg A, Toft N, Jónsson OG, Pruunsild K, Vaitkeviciene G, Vettenranta K, Lund B, Abrahamsson J, Schmiegelow K, Marquart HV. Modvig S, et al. Among authors: lund b. Leukemia. 2019 Jun;33(6):1324-1336. doi: 10.1038/s41375-018-0307-6. Epub 2018 Dec 14. Leukemia. 2019. PMID: 30552401
Risk factors for treatment related mortality in childhood acute lymphoblastic leukaemia.
Lund B, Åsberg A, Heyman M, Kanerva J, Harila-Saari A, Hasle H, Söderhäll S, Jónsson ÓG, Lydersen S, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology. Lund B, et al. Pediatr Blood Cancer. 2011 Apr;56(4):551-9. doi: 10.1002/pbc.22719. Epub 2010 Dec 8. Pediatr Blood Cancer. 2011. PMID: 21298739
Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia.
Levinsen M, Shabaneh D, Bohnstedt C, Harila-Saari A, Jonsson OG, Kanerva J, Lindblom A, Lund B, Andersen EW, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Levinsen M, et al. Among authors: lund b. Eur J Haematol. 2012 Jan;88(1):78-86. doi: 10.1111/j.1600-0609.2011.01695.x. Epub 2011 Oct 2. Eur J Haematol. 2012. PMID: 21854453 Clinical Trial.
NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.
Tulstrup M, Grosjean M, Nielsen SN, Grell K, Wolthers BO, Wegener PS, Jonsson OG, Lund B, Harila-Saari A, Abrahamsson J, Vaitkeviciene G, Pruunsild K, Toft N, Holm M, Hulegårdh E, Liestøl S, Griskevicius L, Punab M, Wang J, Carroll WL, Zhang Z, Dalgaard MD, Gupta R, Nersting J, Schmiegelow K. Tulstrup M, et al. Among authors: lund b. Leukemia. 2018 Dec;32(12):2527-2535. doi: 10.1038/s41375-018-0245-3. Epub 2018 Sep 10. Leukemia. 2018. PMID: 30201983
Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy.
Nersting J, Nielsen SN, Grell K, Paerregaard M, Abrahamsson J, Lund B, Jonsson OG, Pruunsild K, Vaitkeviciene G, Kanerva J, Schmiegelow K; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Nersting J, et al. Among authors: lund b. Cancer Chemother Pharmacol. 2019 Jan;83(1):53-60. doi: 10.1007/s00280-018-3704-7. Epub 2018 Oct 15. Cancer Chemother Pharmacol. 2019. PMID: 30324220
877 results